Innoviva (INVA) Receiving Somewhat Positive Press Coverage, Analysis Finds

News headlines about Innoviva (NASDAQ:INVA) have been trending somewhat positive on Monday, according to Accern Sentiment. Accern rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Innoviva earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.0215241292601 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the media stories that may have impacted Accern’s analysis:

Innoviva (NASDAQ INVA) traded down 0.51% during mid-day trading on Monday, reaching $13.73. The company’s stock had a trading volume of 433,547 shares. The firm has a market cap of $1.50 billion, a PE ratio of 17.27 and a beta of 2.58. The stock’s 50 day moving average is $13.08 and its 200 day moving average is $12.72. Innoviva has a one year low of $8.67 and a one year high of $14.55.

Innoviva (NASDAQ:INVA) last posted its earnings results on Wednesday, July 26th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.02. Innoviva had a negative return on equity of 27.37% and a net margin of 52.56%. The firm had revenue of $58.60 million for the quarter, compared to analyst estimates of $50.53 million. During the same quarter in the prior year, the company earned $0.13 EPS. Innoviva’s revenue was up 80.3% on a year-over-year basis. On average, analysts anticipate that Innoviva will post $1.16 EPS for the current year.

Several research firms have weighed in on INVA. ValuEngine downgraded Innoviva from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Zacks Investment Research downgraded Innoviva from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 16th. Cowen and Company set a $16.00 price target on Innoviva and gave the company a “buy” rating in a research note on Friday, July 28th. Stifel Nicolaus reiterated a “hold” rating and set a $15.00 price target on shares of Innoviva in a research note on Friday, July 28th. Finally, Robert W. Baird reiterated a “neutral” rating and set a $13.00 price target (up previously from $11.00) on shares of Innoviva in a research note on Thursday, July 27th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $15.00.

ILLEGAL ACTIVITY NOTICE: “Innoviva (INVA) Receiving Somewhat Positive Press Coverage, Analysis Finds” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at

About Innoviva

Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Insider Buying and Selling by Quarter for Innoviva (NASDAQ:INVA)

Receive News & Ratings for Innoviva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply